{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:32:10Z","timestamp":1759422730011},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.2169\/internalmedicine.8643-21","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T22:09:49Z","timestamp":1637359789000},"page":"433-438","source":"Crossref","is-referenced-by-count":5,"title":["Successful Use of Certolizumab Pegol for Refractory Psoriatic Arthritis Triggered by COVID-19 Infection"],"prefix":"10.2169","volume":"61","author":[{"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19: 141-154, 2020.","DOI":"10.1038\/s41579-020-00459-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflamm Regen 40: 19, 2020.","DOI":"10.1186\/s41232-020-00131-w"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Niazkar HR, Zibaee B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. Neurol Sci 41: 1667-1671, 2020.","DOI":"10.1007\/s10072-020-04486-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lechien JR, Hervochon R, Hans S. Post-COVID-19 Kawasaki-like syndrome. Ear Nose Throat J 1455613211006011, 2021. Epub ahead of print.","DOI":"10.1177\/01455613211006011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cristiano A, Fortunati V, Cherubini F, Bernardini S, Nuccetelli M. Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies. Clin Rheumatol 40: 2939-2945, 2021.","DOI":"10.1007\/s10067-021-05580-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jacobs J, Eichbaum Q. COVID-19 associated with severe autoimmune hemolytic anemia. Transfusion 61: 635-640, 2021.","DOI":"10.1111\/trf.16226"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Novelli L, Motta F, Ceribelli A, et al. A case of psoriatic arthritis triggered by SARS-CoV-2 infection. Rheumatology (Oxford) 60: e21-e23, 2021.","DOI":"10.1093\/rheumatology\/keaa691"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. H\u00f8nge BL, Hermansen MF, Storgaard M. Reactive arthritis after COVID-19. BMJ Case Rep 14: e241375, 2021.","DOI":"10.1136\/bcr-2020-241375"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jali I. Reactive Arthritis After COVID-19 Infection. Cureus 12: e11761, 2020.","DOI":"10.7759\/cureus.11761"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Saricaoglu EM, Hasanoglu I, Guner R. The first reactive arthritis case associated with COVID-19. J Med Virol 93: 192-193, 2021.","DOI":"10.1002\/jmv.26296"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Ono K, Kishimoto M, Shimasaki T, et al. Reactive arthritis after COVID-19 infection. RMD Open 6: e001350, 2020.","DOI":"10.1136\/rmdopen-2020-001350"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liew IY, Mak TM, Cui L, Vasoo S, Lim XR. A case of reactive arthritis secondary to coronavirus disease 2019 infection. J Clin Rheumatol 26: 233, 2020.","DOI":"10.1097\/RHU.0000000000001560"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. De Stefano L, Rossi S, Montecucco C, Bugatti S. Transient monoarthritis and psoriatic skin lesions following COVID-19. Ann Rheum Dis 2020: annrheumdis-2020-218520.","DOI":"10.1136\/annrheumdis-2020-218520"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Perrot L, Hemon M, Busnel JM, et al. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol 3: e6-e8, 2021.","DOI":"10.1016\/S2665-9913(20)30396-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Derksen VFAM, Kissel T, Lamers-Karnebeek FBG, et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis 2021: annrheumdis-2021-219859.","DOI":"10.1136\/annrheumdis-2021-220516"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033-1034, 2020.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506, 2020.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46: 846-848, 2020.","DOI":"10.1007\/s00134-020-05991-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol 20: 345-346, 2020.","DOI":"10.1038\/s41577-020-0328-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55: 379-390, 2018.","DOI":"10.1007\/s12016-018-8702-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Zhou Q, Vadakekolathu J, Watad A, et al. SARS-CoV-2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell Type-1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights. Front Immunol 12: 635018, 2021.","DOI":"10.3389\/fimmu.2021.635018"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Alivernini S, Cingolani A, Gessi M, et al. Comparative analysis of synovial inflammation after SARS-CoV-2 infection. Ann Rheum Dis 2020: annrheumdis-2020-218315.","DOI":"10.1136\/annrheumdis-2020-218315"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Talarico R, Stagnaro C, Ferro F, Carli L, Mosca M. Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatol 2: e518-e519, 2020.","DOI":"10.1016\/S2665-9913(20)30216-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther 33: e13687, 2020.","DOI":"10.1111\/dth.13687"},{"key":"25","unstructured":"25. Mahil SK, Dand N, Mason KJ, et al.; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 147: 60-71, 2021."},{"key":"26","unstructured":"26. Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80: 930-942, 2021."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79: 700-712, 2020.","DOI":"10.1136\/annrheumdis-2020-218456"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/3\/61_8643-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T03:15:50Z","timestamp":1644030950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/3\/61_8643-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8643-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"article-number":"8643-21"}}